Introduction
============

Silver nanoparticles (AgNPs) have been studied for their effectiveness in the treatment of cancer and infection. AgNPs have been shown to induce death of acute myeloid leukemia and breast cancer cells.[@b1-ijn-11-055],[@b2-ijn-11-055] Additionally, AgNPs conjugated with folic acid are preferentially taken up by human ovary cancer cells, inducing an efficient therapeutic response to irradiation with a continuous wave near-infrared laser.[@b3-ijn-11-055] In addition to anticancer activity, inhibitory effects of AgNPs against various pathogens, including bacteria such as *Escherichia coli*, fungi such as *Candida* species, and viruses such as herpes simplex viruses, have been reported.[@b4-ijn-11-055]--[@b6-ijn-11-055]

AgNP-mediated cytotoxicity has been linked with various cellular processes. AgNPs enter the cytosol, mitochondria, and nucleus,[@b7-ijn-11-055] and uptake of AgNPs has been implicated in their cytotoxicity. AgNPs have been observed in the cytosol of monocytes, which are susceptible to AgNP-mediated cytotoxicity, but not in T-cells, which are resistant to AgNP-mediated cytotoxicity.[@b8-ijn-11-055] Once inside susceptible cells, AgNPs can damage the mitochondria, reduce ATP content, increase reactive oxygen species (ROS) production, damage DNA, and ultimately lead to cell death.[@b7-ijn-11-055] AgNPs can activate p53, extracellular signal-regulated kinase (Erk)1/2, and caspase signaling and downregulate B-cell CLL/lymphoma 2 (Bcl2), resulting in apoptosis.[@b9-ijn-11-055] AgNPs exhibit a strong affinity for the thiol groups found in the antioxidant glutathione (GSH) and may deplete GSH levels in cells; depletion of GSH has been shown to increase the cytotoxicity of AgNPs.[@b10-ijn-11-055]--[@b12-ijn-11-055] A recent report showed an association between autophagy and AgNP cytotoxicity by demonstrating that cell death in AgNP-treated cells increased when autophagy was inhibited.[@b13-ijn-11-055] In addition, a preferential cytotoxic effect of AgNPs was observed in cells of a breast cancer subtype compared to non-tumorigenic cells derived from the breast, liver, kidney, and monocyte lineages, although the underlying mechanisms were not been determined.[@b12-ijn-11-055]

Metabolic reprogramming of tumor cells has emerged as a new therapeutic strategy.[@b14-ijn-11-055] The first metabolic change discovered in tumor cells was the switch from oxidative phosphorylation of glucose to aerobic glycolysis.[@b15-ijn-11-055] Aerobic glycolysis is characterized by increased glucose uptake and lactate release in the presence of oxygen.[@b15-ijn-11-055] Inactivation of lactate dehydrogenase A, which is involved in the last step of aerobic glycolysis, has been shown to suppress tumor growth in a mouse model.[@b16-ijn-11-055] Rapidly growing tumor cells require exogenous glycine and concomitant activation of the glycine synthesis pathway in mitochondria to promote growth.[@b17-ijn-11-055] Tumor cells exhibit different sensitivities to various molecules that inhibit glycolysis, glutamine metabolism, lipid synthesis, and regulation of redox balance. The sensitivity of a tumor is dependent on its metabolic type, which is determined by the preferred pathway of glucose, glycolysis, or lipogenesis.[@b18-ijn-11-055] It was recently shown that the cytotoxicity of melatonin in tumor cells is associated with its suppression of aerobic glycolysis.[@b19-ijn-11-055] However, the effect of AgNPs on tumor cell metabolism has not yet been completely determined.

A recent report demonstrated that zinc oxide nanoparticles, but not titanium dioxide nanoparticles, enhanced glycogenolysis, gluconeogenesis, and glycolysis in a hepatoma cell line.[@b20-ijn-11-055] In this study, we examined the effect of AgNP treatment on glucose metabolism, such as glucose consumption and lactate release, in human hepatoma cell lines. We found that 5 nm AgNPs but not 100 nm AgNPs affected glucose consumption and lactate release as well as the transcription of molecules regulating glucose metabolic pathways. Additionally, we demonstrated that the 5 nm AgNP-mediated reduction in lactate release was restored by treating hepatoma cells with an ROS scavenger.

Materials and methods
=====================

Chemicals
---------

AgNPs of mean sizes 5 and 100 nm were coated with polyvinylpyrrolidone (I&C Technology, Seoul, Korea).

Characterization of AgNPs was previously described.[@b21-ijn-11-055] Briefly, the average size of AgNPs determined using transmission electron microscopy (model JEM-1011, JEOL, Tokyo, Japan) was 7.9±5.3 nm for 5 nm AgNPs and 70.9±71.3 nm for 100 nm AgNPs. AgNPs of 5 nm were round and relatively uniform, whereas 100 nm AgNPs showed a range of different sized particles with most being larger than 50 nm. Agglomeration states of AgNPs in serum-free Roswell Park Memorial Institute (RPMI) 1640 medium (Thermo Fisher Scientific, Waltham, MA, USA) at 1, 10, and 100 mg/mL were analyzed using dynamic light scattering analysis (Novato, CA, USA). Dynamic light scattering showed that the mean diameter of AgNPs was 3.7 and 95.9 nm for 5 nm and 100 nm AgNPs, respectively. *N*-Acetylcysteine (NAC) was purchased from Sigma-Aldrich (St Louis, MO, USA). Propidium iodide was purchased from Millipore (Billerica, MA, USA).

Cell lines and culture
----------------------

The HepG2 cell line (American Type Culture Collection \[ATCC\], Manassas, VA, USA) was originally derived from a hepatocellular carcinoma in a 15-year-old Caucasian boy, and the THP-1 cell line (ATCC) from an acute monocytic leukemia in a 1-year-old male child. The Huh7 cell line (Japanese Collection of Research Bioresources Cell Bank) was originally derived from a hepatocellular carcinoma in a 57-year-old Japanese man. The HepG2 and Huh7 cells were cultured in Dulbecco's Modified Eagle's Medium (Thermo Fisher Scientific) containing 10% fetal bovine serum (Thermo Fisher Scientific), penicillin (100 U/mL, Thermo Fisher Scientific), and streptomycin (100 µg/mL, Thermo Fisher Scientific). The THP-1 cells were cultured in Roswell Park Memorial Institute 1640 (Thermo Fisher Scientific) medium containing 10% fetal bovine serum and penicillin--streptomycin (100 U/mL and 100 µg/mL, respectively) at 37°C in a humidified 5% CO~2~ incubator. Cells that were passaged between 5 and 40 times after thawing were used in the experiments. Ajou University's Institutional Review Board determined this study to be exempt (AJIRB-BMR-EXP-15-426).

Assessment of glucose consumption and lactate production
--------------------------------------------------------

AgNPs were added to the culture of hepatoma cell lines (HepG2 or Huh7 cells) or THP-1 cells. Glucose consumption and lactate production were analyzed using a YSI biochemical analyzer (YSI Life Sciences, Simpsonville, SC, USA). In experiments to block the effect of ROS, 1 mM NAC was added to the culture media 30 minutes before AgNP treatment.

Assessment of cell viability
----------------------------

Cell viability was assessed by labeling with propidium iodide and flow cytometry using a fluorescent-activated cell sorter canto (BD Biosciences, Franklin Lakes, NJ, USA) apparatus.

Western blot analysis
---------------------

Cells were lysed using RIPA buffer for 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3) detection. To analyze nuclear factor erythroid 2-like 2 (Nrf2) levels, cytosolic and nuclear compartments were extracted first with cytosol extraction buffer containing HEPES (10 mM) pH 7.9, KCl (10 mM), EDTA (0.1 mM), 0.3% NP-40, and protease inhibitors and then with nucleus extraction buffer containing HEPES (20 mM) pH 7.9, NaCl (0.4 mM), EDTA (1 mM), 0.25% glycerol, and protease inhibitors. The cell lysate was subjected to Western blot analysis using anti-PFKFB3 antibody (Ab) (Abgent, San Diego, CA, USA), anti-Nrf2 Ab (Santa Cruz Biotechnology, Dallas, TX, USA), anti-actin Ab (Bethyl Laboratories Inc., Montgomery, TX, USA), or anti-lamin A/C Ab (Santa Cruz) as a primary Ab and horseradish peroxidase-conjugated anti-rabbit IgG Ab (Thermo Fisher Scientific) as a secondary Ab. Signals were detected using enhanced chemical luminescence (Amersham, Piscataway, NJ, USA). The immunoblot was digitized using an office scanner (UMAX Astra 4100, Taipei, Taiwan), and the intensity of the band of the expected molecular size was quantitated using Image Gauge V 4.0 (Fujifilm Corporation, Tokyo, Japan). The band intensity of PFKFB3 and cytosolic Nrf2 was normalized to actin, and nuclear Nrf2 was normalized to lamin.

RNA isolation and quantitative reverse transcription-polymerase chain reaction
------------------------------------------------------------------------------

RNA was isolated from cells treated with AgNPs for the indicated time using RNA STAT-60 (Tel-Test, Friendswood, TX, USA). RNA was subjected to quantitative reverse transcription-polymerase chain reaction using primer sets specific to hexokinase-2, PFKFB-3, phosphoenolpyruvate carboxylase (PEPCK)-C, PEPCK-M, Nrf2, transketolase (TKT), phosphogluconate dehydrogenase (6PGD), glucose-6-phosphate dehydrogenase (G6PDH), and transaldolase (TALDO1) (Bioneer, Daejeon, Korea) and Sybr Premix Ex Taq (TaKaRa-Bio, Shiga, Japan). The expression level of each gene was normalized to the expression of actin.

Assessment of intracellular ROS
-------------------------------

Cells were treated with AgNPs for 30 minutes and 1, 2, and 3 hours and then harvested. Cells were washed and then treated with 2,7-dichlorofluorescin diacetate (Thermo Fisher Scientific) in Hank's Balance Salt Solution for 30 minutes at 37°C. Fluorescence intensity was analyzed using a fluorescent-activated cell sorter canto apparatus.

Statistics
----------

Student's *t*-test was performed, and *P*-values were determined to identify significant differences, as indicated in the figures.

Results
=======

Decreased lactate release in cells treated with 5 nm AgNPs
----------------------------------------------------------

We assessed the effect of AgNP treatment on glucose consumption and lactate production. Because the size of AgNPs is a critical determinant of therapeutic activity and toxicity, we compared the effects of 5 nm AgNPs with those of 100 nm AgNPs in HepG2 and Huh7 cells. Glucose consumption over 3 hours was significantly decreased in HepG2 cells treated with 0.5--7.5 µg/mL 5 nm AgNPs in a concentration-dependent manner (*P*\<0.005) but not in cells treated with 100 nm AgNPs ([Figure 1A](#f1-ijn-11-055){ref-type="fig"}). Glucose consumption was not significantly altered in Huh7 cells ([Figure 1D](#f1-ijn-11-055){ref-type="fig"}) or THP-1 cells with or without lipopolysaccharide (LPS) ([Figure 1G](#f1-ijn-11-055){ref-type="fig"}) treated with 5 and 100 nm AgNPs, whereas treatment of HepG2 cells with AgNPs for 6 hours did affect glucose consumption ([Figure S1](#SD1-ijn-11-055){ref-type="supplementary-material"}). Notably, treatment with 5 nm AgNPs, but not 100 nm AgNPs, significantly reduced lactate production in HepG2, Huh7, and LPS-stimulated THP-1 cells in a concentration-dependent manner (*P*\<0.005) ([Figure 1B, E, and H](#f1-ijn-11-055){ref-type="fig"}). Cell viability of HepG2 cells treated with 5 µg/mL and 7.5 µg/mL 5 nm AgNPs was reduced to 90.2% and 61.1%, respectively, but the extent of the reduction in lactate release was similar at both concentrations of AgNP ([Figure 1C](#f1-ijn-11-055){ref-type="fig"}). In addition, when HepG2 cell viability was 92.2% after 6 hours of treatment with 0.5 µg/mL 5 nm AgNPs, lactate release was not reduced ([Figure S1](#SD1-ijn-11-055){ref-type="supplementary-material"}). For Huh7 cells, cell viability was not significantly reduced by treatment with AgNPs for 3 hours ([Figure 1F](#f1-ijn-11-055){ref-type="fig"}). The viability of LPS-stimulated THP-1 cells was reduced to 61.4% after treatment with 5 µg/mL 5 nm AgNPs and to approximately 20.8% after treatment with 7.5 µg/mL 5 nm AgNPs, but the extent of reduction in lactate release was similar at both concentrations of AgNPs ([Figure 1I](#f1-ijn-11-055){ref-type="fig"}). Taken together, these results demonstrated that 5 nm AgNPs reduced lactate release in cells in a dose-dependent manner.

We next examined the kinetic effect of 5 µg/mL AgNPs ([Figure 2](#f2-ijn-11-055){ref-type="fig"}). Glucose consumption was significantly decreased in HepG2 cells 2 hours after treatment with 5 nm AgNPs compared to untreated cells and cells treated with 100 nm AgNPs ([Figure 2A](#f2-ijn-11-055){ref-type="fig"}). The decrease in lactate production was detected at 1 hour after 5 nm AgNP treatment, in both HepG2 and Huh7 cells ([Figure 2B and E](#f2-ijn-11-055){ref-type="fig"}). Cell viability was reduced by 7.2% in HepG2 cells only 3 hours after treatment with 5 nm AgNPs. These results indicate that the decrease in lactate release caused by 5 nm AgNP treatment may occur earlier than the decrease in glucose consumption and cell viability.

Decreased mRNA levels of Nrf2 in cells treated with 5 nm AgNPs
--------------------------------------------------------------

Glucose is metabolized into lactate through glycolysis or generated through gluconeogenesis using substrates such as lactate, amino acids, or glycerol in hepatocytes.[@b22-ijn-11-055] Additionally, glucose is utilized in the pentose phosphate pathway (PPP), in which nicotinamide adenine dinucleotide phosphate hydrogen is synthesized.[@b23-ijn-11-055] Thus, lactate production is reduced if the flux of glucose to glycolysis decreases and/or preferentially diverts to PPP or if gluconeogenesis is increased. To determine whether glucose metabolism is altered by treatment with 5 nm AgNPs, we examined the expression and activation of molecules regulating glycolysis, PPP, or gluconeogenesis. Hexokinase 2 is involved in the conversion of glucose to glucose-6-phosphate, a step shared by glycolysis and PPP. Hexokinase 2 messenger RNA (mRNA) levels in both HepG2 and Huh7 cells treated with AgNPs for 3 hours were not significantly different from those in negative controls ([Figure 3](#f3-ijn-11-055){ref-type="fig"}). PFKFB3 catalyzes the conversion of fructose-6-phosphate to fructose-2,6-bisphosphate, which promotes glycolysis and suppresses gluconeogenesis, whereas PFKFB3 directs PPP when its arginine residues (R131/R134) are not methylated or its cysteine residue is glutathionylated.[@b22-ijn-11-055],[@b24-ijn-11-055],[@b25-ijn-11-055] Although the mRNA levels of PFKFB3 were not significantly altered by treatment with 5 nm AgNPs for 3 hours, its protein levels were generally increased in HepG2 cells treated with 7.5 µg/mL 5 nm AgNPs ([Figures 3](#f3-ijn-11-055){ref-type="fig"} and [4](#f4-ijn-11-055){ref-type="fig"}). At early time points after treatment of hepatoma cells with 5 nm AgNPs, the mRNA levels of PFKFB3 were not significantly changed ([Figure 5A and B](#f5-ijn-11-055){ref-type="fig"}). Cytoplasmic and mitochondrial PEPCK-C and PEPCK-M are involved in gluconeogenesis, using lactate as a substrate.[@b22-ijn-11-055],[@b26-ijn-11-055] Both PEPCK-C and PEPCK-M mRNA levels were not significantly altered in hepatoma cell lines treated with AgNPs for 3 hours compared to those in negative controls ([Figure 3](#f3-ijn-11-055){ref-type="fig"}). Nrf2 participates in glucose metabolism by regulating the expression of enzymes involved in the PPP, such as G6PDH, 6PGD, TKT, and TALDO.[@b27-ijn-11-055] We analyzed the effect of AgNPs on Nrf2 mRNA levels and found that 5 nm AgNPs significantly reduced Nrf2 mRNA levels in both HepG2 and Huh7 cells 2 and 3 hours after treatment with AgNPs, respectively ([Figure 5](#f5-ijn-11-055){ref-type="fig"}). These results suggest that treatment with 5 nm AgNP affects glucose metabolism, since AgNPs altered the expression of Nrf2, a regulator of PPP.

Increased production of ROS without concurrent Nrf2 activation in cells treated with 5 nm AgNPs
-----------------------------------------------------------------------------------------------

Increased ROS production was previously reported in cells treated with AgNPs, and elevated ROS levels were found to be associated with Nrf2 activation to protect cells via nicotinamide adenine dinucleotide phosphate hydrogen-mediated removal of ROS.[@b1-ijn-11-055],[@b28-ijn-11-055]--[@b31-ijn-11-055] Thus, we tested whether 5 nm AgNPs led to ROS production in hepatoma cells and activated Nrf2. Significantly more ROS were produced in HepG2 and Huh7 cells starting at 1 hour and 30 minutes after treatment with 5 nm AgNPs, respectively, compared with negative controls and cells treated with 100 nm AgNPs ([Figure 6](#f6-ijn-11-055){ref-type="fig"}). Further, 5 nm AgNP-induced ROS levels were downregulated in the presence of an ROS scavenger. We then examined the trans-location of Nrf2 to the nucleus after treatment with AgNPs. Nrf2, which is preferentially located in the cytoplasm, moved to the nucleus under elevated ROS levels and induced the transcription of genes harboring antioxidant response elements, including G6PDH, 6PGD, TKT, and TALDO, which are involved in the PPP.[@b31-ijn-11-055] After treatment of HepG2 and Huh7 cells with AgNPs for 1 hour, increased ROS production and decreased lactate release were detected. We then analyzed Nrf2 levels at the indicated times in the cytosolic and nuclear fractions of the cell lysate using Western blotting ([Figure 7](#f7-ijn-11-055){ref-type="fig"}). Because of the low Nrf2 levels in the nuclear fraction, the loading amount of the nuclear fraction was threefold higher than that of the cytosolic fraction. Nuclear Nrf2 density was normalized as follows, owing to contamination of nuclear compartment with cytosolic fraction: \[nuclear Nrf2 intensity - cytosolic Nrf2 intensity × nuclear actin intensity/(cytosolic actin intensity ×3)\]/nuclear lamin density. Unexpectedly, Nrf2 protein levels in the nucleus were not significantly increased in hepatoma cells treated with 5 nm AgNPs compared with negative controls (*P*\>0.01). Additionally, there was no difference in the mRNA levels of genes induced by Nrf2, such as *G6PDH*, *6PGD*, *TKT*, and *TALDO*, between cells treated with AgNPs and negative controls ([Figure S2](#SD2-ijn-11-055){ref-type="supplementary-material"}). Taken together, these results demonstrate that treatment of hepatoma cells with 5 nm AgNPs increased ROS production without activating Nrf2.

ROS scavenger-mediated restoration of lactate release in cells treated with 5 nm AgNPs
--------------------------------------------------------------------------------------

Finally, we investigated whether ROS production was responsible for the reduced release of lactate by hepatoma cells treated with 5 nm AgNPs. We added the ROS scavenger NAC to the hepatoma cell culture prior to treatment with AgNPs and then analyzed glucose consumption, lactate release, and cell viability ([Figure 8](#f8-ijn-11-055){ref-type="fig"}). Reduced glucose consumption by HepG2 cells and lactate release by both hepatoma cell lines following treatment with 5 nm AgNPs were restored after the addition of NAC. These results showed that ROS production induced by 5 nm AgNPs reduced lactate release by the hepatoma cell lines.

Discussion
==========

We showed that 5 nm AgNPs altered glucose metabolism in two different hepatoma cell lines and in THP-1 cells. Reductions in lactate release and Nrf2 transcript levels were observed in both HepG2 and Huh7 cells treated with 5 nm AgNPs. Further, we found that increased ROS production by 5 nm AgNP treatment reduced lactate release.

Our results showed an early effect of AgNPs on glucose metabolism in cells. The reduced release of lactate by hepatoma cell lines was observed from 1 to 6 hours after treatment with 5 nm AgNPs ([Figures 1](#f1-ijn-11-055){ref-type="fig"}, [2](#f2-ijn-11-055){ref-type="fig"}, and S1). A recent report by Chen et al demonstrated a late effect of AgNPs on energy metabolism in several cell lines, including HepG2 cells.[@b32-ijn-11-055] In that report, the metabolic shift from oxidative phosphorylation to glycolysis (ie, increased lactate production) was observed 24 hours after treatment with AgNPs. In addition to this difference in time of analysis after AgNP treatment, there were several other differences between our study and Chen et al, including: 1) the size of AgNPs; we used 5 nm particles, while they used 20 nm or larger particles; 2) we analyzed lactate release into the media, while they measured intracellular lactate; 3) we observed increased ROS production, but they did not; 4) we observed a dose-dependent decrease in cell viability for 6 hours after treatment with AgNPs, but they did not, for 24 hours, using the same concentrations of AgNPs; 5) mRNA levels of PFKFB3 in our study did not significantly increase and its protein levels increased only at a high concentration of AgNP treatment at 3 hours in HepG2 cells, whereas they found an increase in PFKFB3 mRNA levels at 24 hours and no data regarding protein levels were included. Miethling-Graff et al observed size- and dose-dependent effects of AgNPs on ROS production: 1) 5 or 10 µg/mL 10 nm AgNPs increased ROS levels by more than 1.9- or 2.6-fold, respectively, compared to 20, 40, and 60 nm AgNPs; 2) the cytotoxicity of AgNPs showed an inverse relationship with particle size.[@b30-ijn-11-055] Similar to Miethling-Graff's report, we detected elevated ROS levels after 5 nm AgNP treatment, whereas Chen et al did not detect ROS production after 20 nm AgNP treatment. We observed that elevated ROS production played a major role in the reduced release of lactate following 5 nm AgNP treatment, suggesting that metabolic changes caused by AgNPs may depend on the their size. Regarding PFKFB3, the protein levels of PFKFB3 were measured by Western blot and not based only on mRNA levels, suggesting alterations in protein degradation.[@b33-ijn-11-055] Since PFKFB3 can direct the glucose metabolic pathway to glycolysis or to PPP, based on its methylation status,[@b25-ijn-11-055] additional studies are needed to clarify the effect of PFKFB3 on glucose metabolism with AgNP treatment.

Glucose consumption was significantly reduced in HepG2 cells but not in Huh7 and THP-1 cells. Although 5 nm AgNPs reduced lactate release in both HepG2 and Huh7 cells and in THP-1 cells stimulated with LPS, 5 nm AgNPs did not affect lactate release by THP-1 cells in the absence of LPS stimulation. The reasons for these differential responses to AgNP treatment are not well-understood, but several factors may be involved, including the relative contribution of metabolic pathways for energy metabolism or differences in the expression levels and activation status of metabolism regulatory molecules. In agreement with this, various respiration rates were observed in cells depending on the cell type.[@b34-ijn-11-055] Overall, gene expression profiles were similar, but there were differences in the expression of several genes between HepG2 and Huh7 cells.[@b35-ijn-11-055] Our findings suggest that the effect of AgNPs on metabolism may vary according to cell type, and thus further study is necessary to determine the effect of AgNPs on metabolism in the different types of cells.

In our study, PEPCK mRNA levels were not altered, but Nrf2 level was reduced in hepatoma cells 2 hours after AgNP treatment. Further, Nrf2 protein levels and nuclear localization were not significantly increased in hepatoma cells within 1 hour after treatment with AgNPs. In contrast to our results, AgNPs (15 µg/mL) elevated Nrf2 mRNA (approximately 1.8-fold) and protein levels in Caco-2 cells, a human colorectal adenocarcinoma cell line, 3 and 6 hours, respectively.[@b36-ijn-11-055] The previous study found elevated Nrf2 protein levels in the nuclear fraction after normalization of nuclear Nrf2 with GAPDH protein levels.[@b36-ijn-11-055] In another report of rainbow trout (*Oncorhynchus mykiss*) hepatocytes, 10 µg/mL AgNPs with an average size of 9 nm stimulated glycogenolysis and reduced PEPCK activity 48 hours after treatment.[@b37-ijn-11-055] It was not clear whether the alterations in Nrf2 and PEPCK expression were direct effects or were secondary results due to compensation for metabolic changes caused by AgNPs.

Conclusion
==========

We demonstrated ROS-dependent reduction of lactate release by hepatoma cell lines in response to 5 nm AgNPs. Our findings provide important insights into the cytotoxic mechanisms of AgNPs.

Supplementary materials
=======================

###### 

Effect of AgNPs on glucose consumption, lactate release, and cell viability in hepatoma cells treated for 6 hours.

**Notes:** HepG2 (3×10^5^/mL, **A**, **C**, and **E**) and Huh7 cells (2×10^5^/mL, **B**, **D**, and **F**) were treated with the indicated concentrations of 5 or 100 nm AgNPs for 6 hours. Glucose consumption (**A** and **B**) and lactate release (**C** and **D**) in culture media were measured using an YSI biochemical analyzer. Cell viability (**E** and **F**) was analyzed by labeling with propidium iodide and flow cytometry. The data represent the mean ± standard deviation of two independent experiments conducted in triplicate. \**P*\<0.005.

**Abbreviation:** AgNPs, silver nanoparticles.

###### 

Transcript levels of 6PGD, G6PDH, and TALDO1 in hepatoma cells treated with AgNPs.

**Notes:** HepG2 (3×10^5^/mL, **A**) and Huh7 cells (2×10^5^/mL, **B**) were treated with 5 µg/mL 5 or 100 nm AgNPs for 1 hour. Transcript levels were analyzed by real-time RT-PCR. Data are shown as the mean ± standard deviation of two independent experiments conducted in triplicate.

**Abbreviations:** AgNPs, silver nanoparticles; TKT, transketolase; 6PGD, phosphogluconate dehydrogenase; G6PDH, glucose-6-phosphate dehydrogenase; TALDO1, transaldolase; mRNA, messenger RNA; Rel, relative level of; RT-PCR, reverse transcription polymerase chain reaction.
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![Glucose consumption, lactate release, and cell viability of cells treated with various concentrations of silver nanoparticles (AgNPs).\
**Notes:** HepG2 (3×10^5^/mL, **A**, **D**, and **G**) and Huh7 cells (2×10^5^/mL, **B**, **E**, and **H**) were treated with the indicated concentrations of 5 or 100 nm AgNPs for 3 hours. THP-1 cells (5×10^5^/mL, **C**, **F**, and **I**) were pretreated with phorbol myristate acetate (50 ng/mL) for 24 hours and then treated with AgNPs for 5 hours in the presence or absence of LPS (100 ng/mL). Glucose consumption (**A**--**C**) and lactate release (**D**--**F**) in the culture media were measured using a YSI biochemical analyzer. Cell viability (**G**--**I**) was analyzed by labeling with propidium iodide and flow cytometry. The data represent the mean ± standard deviation of two or more independent experiments conducted duplicate or hextuplicate. \**P*\<0.005.\
**Abbreviations:** LPS, lipopolysaccharide; AgNPs, silver nanoparticles.](ijn-11-055Fig1){#f1-ijn-11-055}

![Lactate release by hepatoma cell lines was reduced following treatment with 5 nm AgNPs for 1 hour or more.\
**Notes:** HepG2 (3×10^5^/mL, **A**, **C**, and **E**) and Huh7 cells (2×10^5^/mL, **B**, **D**, and **F**) were treated with 5 µg/mL 5 or 100 nm AgNPs for the indicated times. Glucose consumption (**A** and **B**) and lactate release (**C** and **D**) in culture media were measured using a YSI biochemical analyzer. Cell viability (**E** and **F**) was analyzed by labeling with propidium iodide and flow cytometry. The data represent the mean ± standard deviation of two independent experiments conducted in hextuplicate. \**P*\<0.005.\
**Abbreviation:** AgNPs, silver nanoparticles.](ijn-11-055Fig2){#f2-ijn-11-055}

![Transcript levels of HK2, PFKFB3, PEPCK-C, and PEPCK-M in hepatoma cells treated with AgNPs.\
**Notes:** HepG2 (3×10^5^/mL, **A**, **C**, **E**, and **G**) and Huh7 cells (2×10^5^/mL, **B**, **D**, **F**, and **H**) were treated with the indicated concentrations of 5 or 100 nm AgNPs for 3 hours. Transcript levels were analyzed by real-time RT-PCR. Data are shown as the mean ± standard deviation of three or more independent experiments.\
**Abbreviations:** AgNPs, silver nanoparticles; PFKFB3, 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3; PEPCK-C, phosphoenolpyruvate carboxylase; RT-PCR, reverse transcription polymerase chain reaction; mRNA, messenger RNA.](ijn-11-055Fig3){#f3-ijn-11-055}

![Protein levels of PFKFB3 in hepatoma cells treated with AgNPs.\
**Notes:** HepG2 (3×10^5^/mL, **A**) and Huh7 cells (2×10^5^/mL, **B**) were treated with the indicated concentrations of 5 or 100 nm AgNPs for 3 hours. PFKFB3 expression was analyzed by Western blotting. A representative blot is shown and the normalized band intensity is displayed. Data are shown as the mean ± standard deviation of five independent experiments.\
**Abbreviations:** AgNPs, silver nanoparticles; PFKFB3, 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3.](ijn-11-055Fig4){#f4-ijn-11-055}

![Transcript levels of PFKFB3 and Nrf2 in hepatoma cells treated with AgNPs for various times.\
**Notes:** HepG2 (3×10^5^/mL, **A** and **C**) and Huh7 cells (2×10^5^/mL, **B** and **D**) were treated with 5 µg/mL 5 or 100 nm AgNPs for the indicated times. Relative transcript levels were normalized to actin mRNA level and analyzed by real-time RT-PCR. Data are shown as the mean ± standard deviation of three independent experiments conducted in triplicate. \**P*\<0.005 vs negative control, \*\**P*\<0.005 vs 100 nm.\
**Abbreviations:** AgNPs, silver nanoparticles; PFKFB3, 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3; Nrf2, nuclear factor erythroid 2-like 2; mRNA, messenger RNA; Rel, relative level of; RT-PCR, reverse transcription polymerase chain reaction.](ijn-11-055Fig5){#f5-ijn-11-055}

![Reactive oxygen species (ROS) production in hepatoma cells treated with AgNPs.\
**Notes:** HepG2 (3×10^5^/mL, **A** and **B**) and Huh7 cells (2×10^5^/mL, **C**) were treated with 5 µg/mL 5 or 100 nm AgNPs; 5 nm AgNPs following pretreatment with NAC (1 mM) or H~2~O~2~ for the indicated times. ROS production was determined by DCFDA labeling and flow cytometric analysis. A representative histogram (**A**) of HepG2 at 3 hours and relative percentage of mean fluorescence intensity of two independent experiments conducted in duplicate are shown (**B** and **C**). Data are shown as the mean ± standard deviation.\
**Abbreviations:** AgNPs, silver nanoparticles; PFKFB3, 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3; DCFDA, 2,7-dichlorofluorescin diacetate; NAC, *N*-acetylcysteine; MFI, mean fluorescence intensity.](ijn-11-055Fig6){#f6-ijn-11-055}

![Activation of Nrf2 in hepatoma cells treated with AgNPs.\
**Notes:** HepG2 (3×10^5^/mL, **A**) and Huh7 cells (2×10^5^/mL, **B**) were treated with 5 µg/mL 5 or 100 nm AgNPs for the indicated times. Cytosolic and nuclear Nrf2 were analyzed by Western blotting. A representative blot is shown and the normalized band intensity is displayed. Data are shown as the mean ± standard deviation of four to six independent experiments. \**P*\<0.01 vs 0 time.\
**Abbreviations:** AgNPs, silver nanoparticles; Nrf2, nuclear factor erythroid 2-like 2; Rel, relative level of.](ijn-11-055Fig7){#f7-ijn-11-055}

![Restoration of lactate release in hepatoma cells treated with AgNPs in the presence of an ROS scavenger.\
**Notes:** HepG2 (3×10^5^/mL, **A**, **C**, and **E**) and Huh7 cells (2×10^5^/mL, **B**, **D**, and **F**) were pretreated with 1 mM NAC and then treated with 5 µg/mL 5 nm AgNPs for 3 hours. Glucose consumption (**A** and **B**) and lactate release (**C** and **D**) in the culture media were measured using a YSI biochemical analyzer. Cell viability (**E** and **F**) was analyzed by labeling with propidium iodide and flow cytometry. The data represent the mean ± standard deviation of two independent experiments conducted in triplicate or hextuplicate. \**P*\<0.005.\
**Abbreviations:** AgNPs, silver nanoparticles; ROS, reactive oxygen species; NAC, *N*-acetylcysteine.](ijn-11-055Fig8){#f8-ijn-11-055}
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